We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Regeneron (REGN - Free Report) is expected to reveal quarterly earnings of $8.36 per share, indicating an increase of 1.7% compared to the year-ago period. Analysts forecast revenues of $3.41 billion, representing an increase of 12.5% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 2.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Regeneron metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- Collaboration' should come in at $1.83 billion. The estimate indicates a year-over-year change of +19.8%.
Analysts' assessment points toward 'Revenues- Other Revenue' reaching $145.00 million. The estimate suggests a change of +77.1% year over year.
The combined assessment of analysts suggests that 'Revenues- Net product sales' will likely reach $1.43 billion. The estimate indicates a change of +1% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Total Bayer collaboration revenue' of $308.34 million. The estimate indicates a change of -10.3% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Eylea (Aflibercept)(EYLEA HD and EYLEA)- US' will reach $903.42 million. The estimate points to a change of -13.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Praluent (alirocumab)- US' should arrive at $62.02 million. The estimate indicates a change of +9.2% from the prior-year quarter.
Analysts forecast 'Revenues- Libtayo- US' to reach $244.00 million. The estimate suggests a change of +26.8% year over year.
The average prediction of analysts places 'Revenues- Evkeeza- US' at $38.60 million. The estimate indicates a change of +24.5% from the prior-year quarter.
Analysts expect 'Revenues- Libtayo- ROW' to come in at $116.53 million. The estimate suggests a change of +25.8% year over year.
Analysts predict that the 'Revenues- Kevzara (sarilumab)- US' will reach $81.47 million. The estimate indicates a change of +11.9% from the prior-year quarter.
The consensus estimate for 'Revenues- Praluent (alirocumab)- ROW' stands at $136.46 million. The estimate indicates a change of 0% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Kevzara (sarilumab)- ROW' will reach $50.44 million. The estimate indicates a change of +15.7% from the prior-year quarter.
Over the past month, Regeneron shares have recorded returns of +1.2% versus the Zacks S&P 500 composite's +8.1% change. Based on its Zacks Rank #3 (Hold), REGN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics
The upcoming report from Regeneron (REGN - Free Report) is expected to reveal quarterly earnings of $8.36 per share, indicating an increase of 1.7% compared to the year-ago period. Analysts forecast revenues of $3.41 billion, representing an increase of 12.5% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 2.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Regeneron metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- Collaboration' should come in at $1.83 billion. The estimate indicates a year-over-year change of +19.8%.
Analysts' assessment points toward 'Revenues- Other Revenue' reaching $145.00 million. The estimate suggests a change of +77.1% year over year.
The combined assessment of analysts suggests that 'Revenues- Net product sales' will likely reach $1.43 billion. The estimate indicates a change of +1% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Total Bayer collaboration revenue' of $308.34 million. The estimate indicates a change of -10.3% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Eylea (Aflibercept)(EYLEA HD and EYLEA)- US' will reach $903.42 million. The estimate points to a change of -13.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Praluent (alirocumab)- US' should arrive at $62.02 million. The estimate indicates a change of +9.2% from the prior-year quarter.
Analysts forecast 'Revenues- Libtayo- US' to reach $244.00 million. The estimate suggests a change of +26.8% year over year.
The average prediction of analysts places 'Revenues- Evkeeza- US' at $38.60 million. The estimate indicates a change of +24.5% from the prior-year quarter.
Analysts expect 'Revenues- Libtayo- ROW' to come in at $116.53 million. The estimate suggests a change of +25.8% year over year.
Analysts predict that the 'Revenues- Kevzara (sarilumab)- US' will reach $81.47 million. The estimate indicates a change of +11.9% from the prior-year quarter.
The consensus estimate for 'Revenues- Praluent (alirocumab)- ROW' stands at $136.46 million. The estimate indicates a change of 0% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Kevzara (sarilumab)- ROW' will reach $50.44 million. The estimate indicates a change of +15.7% from the prior-year quarter.
View all Key Company Metrics for Regeneron here>>>Over the past month, Regeneron shares have recorded returns of +1.2% versus the Zacks S&P 500 composite's +8.1% change. Based on its Zacks Rank #3 (Hold), REGN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .